Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Long-term morbidity
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Long-term morbidity

2 evidence topics · 2 sources

Cardiovascular burden in kidney disease

“Heart disease is the most common cause of death among people who have kidney disease.” (opens the source at this quote in a new tab)

Mineral and bone disorder in chronic kidney disease

“bones gradually become thin and weak.” (opens the source at this quote in a new tab)
“bones and joints may begin to feel painful.” (opens the source at this quote in a new tab)